Research Article
The Long-Term Outcomes after Radical Prostatectomy of Patients with Pathologic Gleason 8–10 Disease
Table 3
Kaplan-Meier actuarial estimates of BCR-free survival, metastases-free survival, overall survival, and prostate cancer specific survival (PCSS).
| | Cohort | Overall cohort | pT2/margin − | pT3 or margin + | pT3 & margin + |
| | No at risk/5-year BCR-free survival (CI) | 90/0.69 (0.064–0.74) | 22/0.84 (0.76–0.90) | 25/0.65 (0.55–0.75) | 42/0.64 (0.56–0.68) | | No at risk/5-year mets-free survival (CI) | 90/0.94 (0.91–0.97) | 22/1.00 (1.00–1.00) | 25/0.96 (0.92–1.00) | 42/0.89 (0.84–0.94) | | No at risk/5-year overall survival (CI) | 90/0.96 (0.94–0.98) | 22/1.00 (1.00–1.00) | 25/1.00 (1.00–1.00) | 42/0.92 (0.88–0.96) | | No at risk/5-year PCSS (CI) | 90/0.97 (0.95–0.99) | 22/1.00 (1.00-1.00) | 25/1.00 (1.00-1.00) | 42/0.95 (0.91–0.99) | | No at risk/10-year BCR-free survival (CI) | 47/0.59 (0.53–0.65) | 13/0.77 (0.66–0.88) | 13/0.65 (0.55–0.75) | 21/0.47 (0.38–0.56) | | No at risk/10-year mets-free survival (CI) | 61/0.88 (0.84–0.92) | 16/1.00 (1.00-1.00) | 19/0.96 (0.92–1.00) | 26/0.77 (0.69–0.85) | | No at risk/10-year overall survival (CI) | 65/0.84 (0.79–0.89) | 16/0.85 (0.75–0.95) | 20/0.83 (0.74–0.92) | 29/0.85 (0.79–0.91) | | No at risk/10-year PCSS (CI) | 65/0.94 (0.91–0.97) | 16/1.00 (1.00-1.00) | 20/0.88 (0.80–0.96) | 29/0.95 (0.91–0.99) | | No at risk/15-year BCR-free survival (CI) | 29/0.52 (0.45–0.59) | 8/0.77 (0.66–0.88) | 9/0.45 (0.31–0.59) | 12/0.47 (0.38–0.56) | | No at risk/15-year mets-free survival (CI) | 37/0.88 (0.84–0.92) | 9/1.00 (1.00-1.00) | 12/0.96 (0.92–1.00) | 16/0.77 (0.69–0.85) | | No at risk/15-year overall survival (CI) | 40/0.69 (0.62–0.76) | 9/0.85 (0.75–0.95) | 12/0.74 (0.62–0.86) | 19/0.59 (0.48–0.70) | | No at risk/15-year PCSS (CI) | 40/0.80 (0.73–0.87) | 9/1.00 (1.00-1.00) | 12/0.78 (0.66–0.90) | 19/0.73 (0.62–0.84) |
|
|
